(Total Views: 256)
Posted On: 02/04/2019 10:30:09 AM
Post# of 154853
that was the recent interesting part ..
700mg has already cured these (flu) inflammation breakouts and the VL rebound has been finally explained. This was the actual last important step for monotherapy efficacy!
The small temporary (flu) infections caused a higher CCR5 count and hence CCR5 occupancy via 350mg PRO140 has been reduced and the VL rebound happened.
Now 700mg just cured that, no need to pause ...
This news should have lifted the stock already, but probably hasn't yet been realized in the markets yet. But it surely will, since FDA also is quite impressed with the results, see last PR.
Quote:
To expand to mono only, I'm at 50/50. The FDA might look and see these spikes in VL when patients get the flu, etc, and feel they should have another drug working in a different way helping suppress VL in these situations. Or maybe the FDA will see some other issue, hard to say, which is why I am at 50/50. There is a reason no one has ever been approved for mono, very hard hill to climb.
700mg has already cured these (flu) inflammation breakouts and the VL rebound has been finally explained. This was the actual last important step for monotherapy efficacy!
The small temporary (flu) infections caused a higher CCR5 count and hence CCR5 occupancy via 350mg PRO140 has been reduced and the VL rebound happened.
Now 700mg just cured that, no need to pause ...
This news should have lifted the stock already, but probably hasn't yet been realized in the markets yet. But it surely will, since FDA also is quite impressed with the results, see last PR.
(0)
(0)
